Ultragenyx Pharmaceutical
RARE
223 hedge funds and large institutions have $4.03B invested in Ultragenyx Pharmaceutical in 2022 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 85 increasing their positions, 73 reducing their positions, and 46 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 73
0.45% less ownership
Funds ownership: 97.03% → 96.58% (-0.45%)
7% less funds holding
Funds holding: 239 → 223 (-16)
14% less call options, than puts
Call options by funds: $12.6M | Put options by funds: $14.7M
16% less capital invested
Capital invested by funds: $4.79B → $4.03B (-$764M)
24% less first-time investments, than exits
New positions opened: 35 | Existing positions closed: 46
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
+$64.3M |
| 2 |
CCM
Cadian Capital Management
New York
|
+$47.9M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
+$37.6M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
+$32M |
| 5 |
State Street
Boston,
Massachusetts
|
+$31.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Capital World Investors
Los Angeles,
California
|
-$81.2M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$68M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$18.3M |
| 4 |
O
OrbiMed
New York
|
-$16.5M |
| 5 |
BC
Boxer Capital
San Diego,
California
|
-$14.5M |
RARE Hedge Fund Activity: Q2 2022 in Review
223 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in Ultragenyx Pharmaceutical (RARE) for Q2 2022, worth a combined $4.03B — down 16% from $4.79B a quarter earlier.
Sellers outnumbered buyers: 46 funds closed out of RARE and 35 opened new positions — a net loss of 11 holders — while 73 trimmed existing stakes and 85 added.
The largest buyer was Wellington Management Group, adding an estimated $64.3M. The largest seller was Capital World Investors, cutting an estimated $81.2M.
- 223 institutional investors held Ultragenyx Pharmaceutical (RARE) as of Q2 2022, down from 239 in Q1 2022.
- Funds reported $4.03B of Ultragenyx Pharmaceutical stock for Q2 2022, down 16% quarter-over-quarter.
- 35 funds opened new Ultragenyx Pharmaceutical positions in Q2 2022 and 46 closed out, a net change of -11 holders.
- The largest Ultragenyx Pharmaceutical buyer in Q2 2022 was Wellington Management Group, an estimated $64.3M added.
- The largest Ultragenyx Pharmaceutical seller in Q2 2022 was Capital World Investors, an estimated $81.2M sold.
Based on aggregated 13F filings for Q2 2022.